[HTML][HTML] The therapeutic potential of mesenchymal stem cells for cardiovascular diseases
Y Guo, Y Yu, S Hu, Y Chen, Z Shen - Cell Death & Disease, 2020 - nature.com
Mesenchymal stem cells (MSCs) are derived from a wide range of sources and easily
isolated and cultured. MSCs have the capacity for in vitro amplification and self-renewal, low …
isolated and cultured. MSCs have the capacity for in vitro amplification and self-renewal, low …
[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the …
RP Giugliano, TR Pedersen, JG Park, GM De Ferrari… - The Lancet, 2017 - thelancet.com
Background LDL cholesterol is a well established risk factor for atherosclerotic
cardiovascular disease. How much one should or safely can lower this risk factor remains …
cardiovascular disease. How much one should or safely can lower this risk factor remains …
Effect of vupanorsen on non–high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70
BA Bergmark, NA Marston, CR Bramson, M Curto… - Circulation, 2022 - Am Heart Assoc
Background: Genetic loss-of-function variants in ANGPTL3 are associated with lower levels
of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits …
of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits …
[HTML][HTML] Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
R García-Maset, J Bover, JS de la Morena… - nefrologia, 2022 - Elsevier
La enfermedad renal crónica (ERC) es un importante problema de salud pública a nivel
mundial afectando a más del 10% de la población española. Se asocia a elevada …
mundial afectando a más del 10% de la población española. Se asocia a elevada …
Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart …
South Asians (from Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, and Sri
Lanka) make up one quarter of the world's population and are one of the fastest-growing …
Lanka) make up one quarter of the world's population and are one of the fastest-growing …
Residual cardiovascular risk at low LDL: remnants, lipoprotein (a), and inflammation
RC Hoogeveen, CM Ballantyne - Clinical Chemistry, 2021 - academic.oup.com
Background Current guidelines target low-density lipoprotein cholesterol (LDL-C)
concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet …
concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet …
Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries
Background and aims One of the objectives of the ESC-EORP EUROASPIRE V survey is to
determine how well European guidelines on the management of dyslipidaemias are …
determine how well European guidelines on the management of dyslipidaemias are …
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new …
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and …
Y Handelsman, PS Jellinger, CK Guerin… - Endocrine practice, 2020 - Elsevier
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …